NY-PHILIP-MORRIS-INTL
9.10.2020 08:29:10 CEST | Business Wire | Press release
Philip Morris International Inc. (PMI) (NYSE:PM) is pleased to announce the appointment of Jennifer Motles to the position of Chief Sustainability Officer, effective November 1, 2020. Ms. Motles will succeed current CSO Huub Savelkouls, who will retire after almost three decades of distinguished service.
Ms. Motles will report to the company’s CFO, Emmanuel Babeau, as it is increasingly recognized—by both companies and investors—that fully integrating environmental, social, and governance (ESG) drivers into business strategy can significantly enhance both the sustainability agendas and financial performance.
“Integrating sustainability and financial strategies is further recognition of our commitment to unsmoking our planet and transforming our company,” said PMI’s CEO, André Calantzopoulos. “It is a logical next step for us, following our Statement of Purpose adopted by our Board and the introduction of Integrated Reporting earlier this year.”
Ms. Motles joined PMI in 2015, when she helped craft PMI’s sustainability strategy, ensuring it was intrinsically linked to the adoption of the company’s vision of delivering a smoke-free future. Since then, she has helped advance PMI’s transformation, honing the company’s sustainability and ESG performance, with a strong focus on shareholder and stakeholder engagement.
“This move outlines that ESG is core to PMI’s performance and success, and further demonstrates PMI’s leadership in sustainability and corporate purpose,” said Mr. Babeau. “Jennifer, with her broad range of international experience and her proven track record in the domain, is the ideal candidate to lead our company’s ambitious sustainability agenda.”
“It is our firm belief that sustainability and business performance do not follow separate paths and narratives. They are fully interrelated and mutually reinforcing and should be organized and presented to all stakeholders in an integrated way,” continued Mr. Babeau.
Addressing the health impacts of cigarettes while working relentlessly to convince the hundreds of millions of men and women who would otherwise continue smoking to switch to noncombustible and therefore smoke-free alternatives is the most important contribution we can make to a sustainable world and to a sustainable PMI. This monumental effort is the cornerstone of PMI’s purpose and business strategy. PMI’s hopes and ambition are that all stakeholders of the company will embrace and support this mission.
Ms. Motles began her career working for the Chilean Office of Drugs & Crime Prevention and Prosecution. She gained international experience working for organizations such as UNCITRAL, UNODC’s Terrorism Prevention Branch, and the UNCTAD/WTO’s International Trade Center. Prior to joining PMI, Jennifer worked for the government of Israel, representing the country as its Human Rights & Humanitarian Affairs Officer at the United Nations and other international organizations.
She holds a JD degree from Universidad de Chile—Escuela de Derecho, and an LLM degree from University of California, Berkeley School of Law, as well as specialized diplomas in Women’s Human Rights, Behavioral Economics, Sustainability, Sustainable Finance, and Political Affairs from IHEID, Harvard Business School, the Harvard School of Public Health, and Stanford University.
“This announcement wouldn’t be complete without acknowledging our gratitude to Huub for his many accomplishments,” added Mr. Calantzopoulos. “In honor of his retirement, we celebrate him and wish him the best in his next chapter.”
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company, and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the United States. PMI ships a version of its smoke-free devices and consumables authorized by the U.S. Food and Drug Administration to Altria Group, Inc. for sale in the United States under license. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities, and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. For more information, please visit www.pmi.com and www.pmiscience.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201008005939/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PNCC Selects LotusFlare to Power Digital BSS and Commerce Platform for New 4G/5G Standalone Network26.2.2026 13:04:00 CET | Press release
LotusFlare, a provider of a cloud-native, AI-driven digital commerce and monetization platform for communications service providers (CSPs), today announced that Palau National Communications Corporation (PNCC) has selected it to provide a comprehensive commerce and monetization platform, including a full-stack digital business support system (dBSS) as part of PNCC’s broader 4G/5G Standalone (SA) network modernization programme. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226869218/en/ Palau National Communications Corporation (PNCC) The LotusFlare solution will support PNCC subscribers across mobile, fixed broadband, and digital TV services, while enabling unique multi-tenant capabilities aligned with PNCC’s long-term digital and regional strategy. PNCC has embarked on a comprehensive technology modernization program focused on increasing speed-to-market, enhancing customer experience, and long-term operational efficie
GoldState Music and Bridgepoint Announce Strategic Partnership Targeting Growth Investments26.2.2026 13:00:00 CET | Press release
Capital will support GoldState Music’s Growth Strategy which will invest in scalable, profitable music-oriented businesses across the music value chainBridgepoint commits a significant investment as lead investor in GoldState’s Growth Strategy Bridgepoint, one of the world’s leading mid-market investors, today announced that it has entered into a strategic partnership with GoldState Music, a premier music investment platform, committing a significant investment as lead investor in GoldState’s Growth Strategy. The capital will support a dedicated investment programme focused on building and scaling high-quality music-oriented businesses globally. GoldState Music is a private investment firm founded in 2022 by industry veteran Charles Goldstuck, who played an integral role in the development of many music enterprises as well as in the careers of numerous major artists and songwriters. The company’s Growth Strategy is focused on investing in and scaling growing businesses operating in the
Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics26.2.2026 13:00:00 CET | Press release
Transformative clinical pipeline transaction will add CL-273, a pan-EGFR inhibitor, and CL-741, a Phase 1-Ready c-MET inhibitor, to Kairos Pharma's clinical portfolio to target multi-billion dollar lung cancer market. Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces the signing of a term sheet for a strategic asset acquisition with Celyn Therapeutics, Inc., a privately held biotechnology company backed by OrbiMed and Torrey Pines Investment. Under the proposed terms of the agreement, Kairos Pharma will acquire worldwide rights to two highly differentiated, clinical-stage oncology assets targeting non-small cell lung cancer (NSCLC): CL-273, a pre-IND, reversible, wild-type-sparing pan-EGFR inhibitor, and CL-741, a Phase 1-ready, orally available type IIb c-MET kinase inhibitor. John Yu, M.D., Kairos Pharma Chief Executive Officer, commented: "We anticipate this acquisition will significantly
Amazfit Introduces the Active 3 Premium: Turning Daily Movement into Meaningful Progress for Entry-Level Runners26.2.2026 13:00:00 CET | Press release
Premium materials, a 12-day battery life and new running features provide support for those kicking off their running journey Amazfit, a leading global smart wearable brand owned by Zepp Health, today announced the Amazfit Active 3 Premium, a compact, 4-button smartwatch designed as an entry point into structured running and hybrid training. Made for athletes building consistency across different forms of training, the Active 3 Premium supports road running and hybrid routines that combine endurance, strength, and studio-based workouts. Its compact design makes it easy to train across environments, from neighborhood runs to studio floors, offering a capable, approachable experience without feeling overbuilt or intimidating. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226378156/en/ Made for athletes building consistency across different forms of training, the Active 3 Premium supports road running and hybrid routines th
Wyss Geneva Spin-Off Clee Medical Secures Seed Financing to Bring Real-Time Vision to Brain Surgery26.2.2026 12:49:00 CET | Press release
The Wyss Center for Bio and Neuroengineering Geneva announced today the successful closing of the Seed financing round of Clee Medical SA, a Swiss neurotechnology spin-off developing ultra-high-resolution real-time intraoperative imaging for brain surgery. The round was led by High-Tech Gründerfonds (HTGF), with participation from Zürcher Kantonalbank (ZKB), Kickfund, FONGIT, and Venture Kick joining existing investors Wyss Center Geneva. Clee Medical spun-out from Wyss Geneva’s Minimally Invasive Intracranial Access (MICA) research project in December 2024. Its flagship platform, Neuro Access, combines OCT imaging with advanced navigation to help neurosurgeons visualize brain anatomy and critical structures in real time during stereotactic procedures. “Clee Medical not only holds the promise of improving patient outcomes but also highlights Wyss Geneva’s dedication to bridging the gap between scientific discovery and real-world impact.” Dr. Erwin Böttinger, CEO, Wyss Geneva “Neurosurg
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
